API | lersivirine

lersivirine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus (HIV). NNRTIs inhibit reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of HIV. RT is one of the most popular targets in the field of antiretroviral drug development. ^Wikipedia

Chemistry

SMILES: CCc1nn(CCO)c(CC)c1Oc2cc(cc(c2)C#N)C#N
InChIKey: MCPUZZJBAHRIPO-UHFFFAOYSA-N
Mol. Mass: 310.36
ALogP: 2.54 Partition coefficient
ChEMBL Molecule:
lersivirine

More Chemistry

Pharmacology

Mechanism of Action:
- Reverse transcriptase (Human immunodeficiency virus 2) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5-((3,5-diethyl-1-(2-hydroxyethyl)(3,5-14c2)-1h-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile | lersivirine | uk453061 | uk 453061 | uk 453,061 | uk-453061 | uk-453,061 | uk453,061

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Healthy Volunteers (Phase 1)

HIV-1 (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 12
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue